Amedisys Interest Income vs Operating Income Analysis

AMED Stock

USD 91.15 4.86 5.06%

Amedisys financial indicator trend analysis is way more than just evaluating Amedisys prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amedisys is a good investment. Please check the relationship between Amedisys Interest Income and its Operating Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Interest Income vs Operating Income

Interest Income vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amedisys Interest Income account and Operating Income. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Amedisys' Interest Income and Operating Income is -0.02. Overlapping area represents the amount of variation of Interest Income that can explain the historical movement of Operating Income in the same time period over historical financial statements of Amedisys, assuming nothing else is changed. The correlation between historical values of Amedisys' Interest Income and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Income of Amedisys are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Interest Income i.e., Amedisys' Interest Income and Operating Income go up and down completely randomly.

Correlation Coefficient

-0.02

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Operating Income

Operating Income is the amount of profit realized from Amedisys operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Amedisys is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Amedisys' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amedisys current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.At present, Amedisys' Sales General And Administrative To Revenue is projected to increase slightly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 16.65, whereas Discontinued Operations is forecasted to decline to (260.8 K).

	2021	2022	2023	2024 (projected)
Gross Profit	980.8M	962.8M	457.1M	447.4M
Total Revenue	2.2B	2.2B	2.2B	2.3B

Gross Profit Total Revenue

Amedisys fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Current Deferred Revenue	Common Stock Total Equity	Common Stock
Total Assets		0.96	-0.34	0.93	0.99	0.11	0.9	0.95	0.6	0.74	0.99	-0.37	0.74	0.95	0.35	0.96	0.29	0.72	-0.09	0.99	-0.16	0.95	0.9	0.76	0.52	0.53
Short Long Term Debt Total	0.96		-0.4	0.81	0.93	0.1	0.98	0.95	0.53	0.62	0.97	-0.42	0.62	0.86	0.2	1.0	0.27	0.73	-0.25	0.97	-0.29	0.85	0.89	0.72	0.38	0.39
Other Current Liab	-0.34	-0.4		-0.13	-0.36	-0.03	-0.48	-0.41	-0.42	0.08	-0.38	1.0	0.08	-0.28	-0.1	-0.41	-0.05	-0.35	0.16	-0.31	0.06	-0.2	-0.24	-0.44	-0.15	-0.15
Total Current Liabilities	0.93	0.81	-0.13		0.91	0.16	0.73	0.82	0.58	0.76	0.9	-0.16	0.76	0.91	0.42	0.82	0.44	0.52	0.05	0.93	-0.1	0.93	0.85	0.64	0.57	0.58
Total Stockholder Equity	0.99	0.93	-0.36	0.91		0.11	0.86	0.93	0.64	0.75	0.98	-0.38	0.75	0.97	0.41	0.93	0.23	0.75	-0.03	0.97	-0.11	0.95	0.88	0.76	0.57	0.58
Property Plant And Equipment Net	0.11	0.1	-0.03	0.16	0.11		0.14	-0.06	0.15	-0.13	0.17	-0.03	-0.13	0.02	0.46	0.08	0.19	0.32	0.47	0.12	-0.24	0.02	0.2	-0.04	0.46	0.46
Net Debt	0.9	0.98	-0.48	0.73	0.86	0.14		0.9	0.56	0.44	0.92	-0.5	0.44	0.78	0.19	0.97	0.28	0.68	-0.27	0.91	-0.29	0.74	0.83	0.63	0.37	0.37
Retained Earnings	0.95	0.95	-0.41	0.82	0.93	-0.06	0.9		0.47	0.69	0.94	-0.43	0.69	0.87	0.08	0.96	0.17	0.66	-0.39	0.94	-0.09	0.85	0.87	0.81	0.28	0.29
Accounts Payable	0.6	0.53	-0.42	0.58	0.64	0.15	0.56	0.47		0.17	0.6	-0.43	0.17	0.66	0.74	0.53	0.11	0.43	0.37	0.58	0.04	0.56	0.43	0.13	0.78	0.78
Cash	0.74	0.62	0.08	0.76	0.75	-0.13	0.44	0.69	0.17		0.69	0.05	1.0	0.76	0.12	0.63	0.09	0.54	-0.06	0.71	-0.16	0.85	0.7	0.74	0.26	0.28
Non Current Assets Total	0.99	0.97	-0.38	0.9	0.98	0.17	0.92	0.94	0.6	0.69		-0.4	0.69	0.92	0.35	0.97	0.25	0.75	-0.1	0.99	-0.17	0.91	0.88	0.75	0.52	0.53
Non Currrent Assets Other	-0.37	-0.42	1.0	-0.16	-0.38	-0.03	-0.5	-0.43	-0.43	0.05	-0.4		0.05	-0.3	-0.1	-0.43	-0.06	-0.37	0.17	-0.33	0.07	-0.22	-0.26	-0.46	-0.15	-0.15
Cash And Short Term Investments	0.74	0.62	0.08	0.76	0.75	-0.13	0.44	0.69	0.17	1.0	0.69	0.05		0.76	0.12	0.63	0.09	0.54	-0.06	0.71	-0.16	0.85	0.7	0.74	0.26	0.28
Net Receivables	0.95	0.86	-0.28	0.91	0.97	0.02	0.78	0.87	0.66	0.76	0.92	-0.3	0.76		0.46	0.87	0.27	0.64	0.04	0.93	-0.01	0.98	0.84	0.7	0.6	0.61
Common Stock Shares Outstanding	0.35	0.2	-0.1	0.42	0.41	0.46	0.19	0.08	0.74	0.12	0.35	-0.1	0.12	0.46		0.2	0.2	0.36	0.83	0.3	0.13	0.41	0.13	-0.04	0.96	0.96
Non Current Liabilities Total	0.96	1.0	-0.41	0.82	0.93	0.08	0.97	0.96	0.53	0.63	0.97	-0.43	0.63	0.87	0.2		0.26	0.72	-0.25	0.97	-0.28	0.85	0.87	0.73	0.39	0.39
Inventory	0.29	0.27	-0.05	0.44	0.23	0.19	0.28	0.17	0.11	0.09	0.25	-0.06	0.09	0.27	0.2	0.26		-0.16	0.11	0.35	-0.16	0.35	0.33	0.19	0.24	0.25
Other Current Assets	0.72	0.73	-0.35	0.52	0.75	0.32	0.68	0.66	0.43	0.54	0.75	-0.37	0.54	0.64	0.36	0.72	-0.16		0.1	0.67	-0.24	0.63	0.63	0.56	0.45	0.45
Other Stockholder Equity	-0.09	-0.25	0.16	0.05	-0.03	0.47	-0.27	-0.39	0.37	-0.06	-0.1	0.17	-0.06	0.04	0.83	-0.25	0.11	0.1		-0.14	-0.02	0.05	-0.19	-0.31	0.69	0.68
Total Liab	0.99	0.97	-0.31	0.93	0.97	0.12	0.91	0.94	0.58	0.71	0.99	-0.33	0.71	0.93	0.3	0.97	0.35	0.67	-0.14		-0.21	0.93	0.9	0.73	0.48	0.49
Property Plant And Equipment Gross	-0.16	-0.29	0.06	-0.1	-0.11	-0.24	-0.29	-0.09	0.04	-0.16	-0.17	0.07	-0.16	-0.01	0.13	-0.28	-0.16	-0.24	-0.02	-0.21		-0.1	-0.32	-0.12	0.1	0.09
Total Current Assets	0.95	0.85	-0.2	0.93	0.95	0.02	0.74	0.85	0.56	0.85	0.91	-0.22	0.85	0.98	0.41	0.85	0.35	0.63	0.05	0.93	-0.1		0.85	0.73	0.56	0.57
Short Term Debt	0.9	0.89	-0.24	0.85	0.88	0.2	0.83	0.87	0.43	0.7	0.88	-0.26	0.7	0.84	0.13	0.87	0.33	0.63	-0.19	0.9	-0.32	0.85		0.74	0.32	0.33
Current Deferred Revenue	0.76	0.72	-0.44	0.64	0.76	-0.04	0.63	0.81	0.13	0.74	0.75	-0.46	0.74	0.7	-0.04	0.73	0.19	0.56	-0.31	0.73	-0.12	0.73	0.74		0.15	0.16
Common Stock Total Equity	0.52	0.38	-0.15	0.57	0.57	0.46	0.37	0.28	0.78	0.26	0.52	-0.15	0.26	0.6	0.96	0.39	0.24	0.45	0.69	0.48	0.1	0.56	0.32	0.15		1.0
Common Stock	0.53	0.39	-0.15	0.58	0.58	0.46	0.37	0.29	0.78	0.28	0.53	-0.15	0.28	0.61	0.96	0.39	0.25	0.45	0.68	0.49	0.09	0.57	0.33	0.16	1.0

Click cells to compare fundamentals

Amedisys Account Relationship Matchups

Amedisys fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.3B	1.6B	1.9B	2.0B	2.1B	2.2B
Short Long Term Debt Total	326.1M	307.0M	545.6M	537.9M	487.2M	511.6M
Other Current Liab	(3.1M)	313.1M	(3.4M)	(20.1B)	382.9M	402.0M
Total Current Liabilities	326.9M	456.3M	374.3M	355.5M	473.7M	497.4M
Total Stockholder Equity	640.5M	809.2M	931.4M	1.1B	1.1B	1.1B
Property Plant And Equipment Net	112.9M	117.2M	119.7M	118.9M	130.8M	76.0M
Net Debt	295.8M	225.2M	502.9M	497.4M	341.4M	358.4M
Retained Earnings	246.4M	430.0M	639.1M	757.7M	747.9M	785.3M
Accounts Payable	31.3M	42.7M	38.2M	43.7M	28.2M	19.0M
Cash	30.3M	81.8M	42.7M	40.5M	145.9M	153.2M
Non Current Assets Total	912.2M	1.2B	1.5B	1.6B	1.6B	1.6B
Non Currrent Assets Other	18.9M	19M	19.9M	(20.4B)	(35.2M)	(37.0M)
Cash And Short Term Investments	30.3M	81.8M	42.7M	40.5M	145.9M	153.2M
Net Receivables	237.6M	255.1M	275.0M	296.8M	328.2M	344.6M
Common Stock Shares Outstanding	33.0M	33.3M	33.0M	32.7M	32.6M	23.4M
Liabilities And Stockholders Equity	1.3B	1.6B	1.9B	2.0B	2.1B	2.2B
Non Current Liabilities Total	294.3M	300.1M	506.4M	514.1M	466.7M	490.0M
Inventory	74.4M	11.8M	13.4M	25.2M	29.0M	30.5M
Other Current Assets	8.2M	13.3M	25.6M	26.4M	22.9M	24.0M
Other Stockholder Equity	394.0M	379.2M	292.3M	293.9M	318.6M	264.1M
Total Liab	621.2M	756.5M	880.6M	869.7M	940.4M	987.4M
Property Plant And Equipment Gross	28.1M	117.2M	216.6M	220.2M	368.6M	350.2M
Total Current Assets	350.6M	362.0M	356.7M	389.0M	496.9M	521.8M
Short Term Debt	37.7M	40.5M	44.2M	49.0M	62.6M	65.7M
Current Deferred Revenue	261.1M	60M	295.2M	20.4B	23.5B	24.6B
Other Liab	5.9M	33.6M	5.0M	25.2M	29.0M	30.5M
Other Assets	12K	174.6M	73.3M	39.3M	45.2M	47.5M
Long Term Debt	232.3M	204.5M	432.1M	419.4M	361.9M	380.0M
Treasury Stock	(251.2M)	(319.1M)	(435.9M)	(461.2M)	(415.1M)	(394.3M)
Property Plant Equipment	28.1M	23.7M	119.7M	16.0M	18.4M	17.5M
Good Will	658.5M	932.7M	1.2B	1.3B	1.2B	1.3B
Intangible Assets	64.7M	74.2M	111.2M	101.2M	102.7M	64.1M
Net Tangible Assets	(82.8M)	(197.6M)	(375.9M)	(337.0M)	(303.3M)	(288.1M)
Noncontrolling Interest In Consolidated Entity	1.1M	1.5M	45.0M	55M	63.3M	66.4M
Retained Earnings Total Equity	246.4M	430.0M	639.1M	757.7M	871.3M	914.9M
Long Term Debt Total	232.3M	204.5M	432.1M	419.4M	482.3M	506.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:

How To Invest In Amedisys

Details

Is Amedisys Stock a good investment?

Details

What is Amedisys' Net Worth?

Details

Largest Health Care Providers & Services Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Amedisys Stock analysis

When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.

	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk

Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.43)

Earnings Share

(0.64)

Revenue Per Share

69.004

Quarterly Revenue Growth

0.027

Return On Assets

0.0626

The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amedisys Interest Income vs Operating Income Analysis

Interest Income vs Operating Income

Interest Income vs Operating Income Correlation Analysis

Correlation Coefficient

Interest Income

Operating Income

Amedisys fundamental ratios Correlations

Amedisys Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amedisys fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Amedisys Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Non Currrent Assets Other	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets

Non Currrent Assets Other	- 0.5	Net Debt
Net Debt	- 0.48	Other Current Liab
Current Deferred Revenue	- 0.46	Non Currrent Assets Other
Current Deferred Revenue	- 0.44	Other Current Liab
Non Current Liabilities Total	- 0.43	Non Currrent Assets Other
Non Currrent Assets Other	- 0.43	Accounts Payable